DURHAM, N.C.--(BUSINESS WIRE)--Aug. 17, 2006--Argos Therapeutics today announced that dosing has been initiated in a Phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer (metastatic renal cell carcinoma). AGS-003 is a second-generation dendritic cell-based therapy with optimized immune response characteristics that is designed to stimulate the patient’s immune system to target and destroy the patient’s cancer cells.
